Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Testing HRD in the clinic

Isabelle Ray-Coquard • 1 Sep 2021
ESMO 2021
Gynecological Cancer Olaparib
PRIMA

Isabelle Ray-Coquard, MD, PhD, of the Léon Bérard Center and the Claude Bernard University Lyon 1, Lyon, France, discusses how PARP inhibitors play a large role in maintenance therapy in first-line settings for ovarian cancer and the importance of homologous recombination deficiency (HRD) testing in the clinic. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.

More from Isabelle Ray-Coquard

0:38
Personalized medicine for patients with gynecological sarcoma
Isabelle Ray-Coquard • 23 Oct 2021
0:46
PARP inhibitor rechallenging in ovarian cancer
Isabelle Ray-Coquard • 23 Oct 2021
1:08
Should 1L maintenance with PARP inhibitors be given to all patients with ovarian cancer?
Isabelle Ray-Coquard • 23 Oct 2021
1:16
KEYNOTE 826: pembrolizumab + chemo in patients with advanced cervical cancer
Isabelle Ray-Coquard • 1 Sep 2021

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals